Search

everythinglearnresearchcommunity

for

Search:↓

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

Low vitamin D levels are common in people with Alopecia Areata.

This therapy effectively treats resistant alopecia areata with minimal side effects.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

COVID-19 doesn't make alopecia areata worse.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.

Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.

People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

PRP treatment may help with alopecia areata, especially in newer cases.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

AB+ blood group is more common in alopecia areata patients.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.